University of Utah
Hematology and Oncology fellowship · Salt Lake City, UT · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of Utah's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About University of Utahinstitution-wide hematology and oncology research
Hematology and Oncology publications from University of Utah and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
324
works per year
17th of 74 hematology and oncology fellowship programs
+3.0%
2-year growth
57th of 74 hematology and oncology fellowship programs
26.6%
in top 10% of field (works before 2025)
27th of 72 hematology and oncology fellowship programs
47.8%
cited above world average
19th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 1,001Hematology · 574
Hematology and Oncology research topics at University of Utah
Papers in the window; each links to the list on OpenAlex.
- Cancer survivorship and care 124
- Multiple Myeloma Research and Treatments 118
- CAR-T cell therapy research 118
- Cancer Immunotherapy and Biomarkers 117
- Acute Myeloid Leukemia Research 101
- Cutaneous Melanoma Detection and Management 101
- Colorectal Cancer Screening and Detection 99
- Hematopoietic Stem Cell Transplantation 93
Most cited at University of Utah since 2024
All hematology and oncology papers there on OpenAlex
- Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C. Issa et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 262
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenSumit Gupta et al. · New England Journal of Medicine · 2024 · PubMed · cited 240
- Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Kayleigh Pavitra Bhangdia et al. · The Lancet Oncology · 2026 · PubMed · cited 174
- CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta Kumar Pal et al. · Cancer Discovery · 2024 · PubMed · cited 173
- Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana et al. · Blood · 2024 · PubMed · cited 158
- Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 155
- Platelet TransfusionRyan A. Metcalf et al. · JAMA · 2025 · PubMed · cited 140
- Supramolecular Coordination Complexes for Synergistic Cancer TherapyYang Li et al. · Accounts of Chemical Research · 2024 · PubMed · cited 107
- Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P. Iyer et al. · The Lancet Oncology · 2024 · PubMed · cited 91
- Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R. Power et al. · European Heart Journal · 2025 · PubMed · cited 90